Hikma Pharmaceuticals Plc Holding(s) in Company (2018R)
October 23 2013 - 6:40AM
UK Regulatory
TIDMHIK
RNS Number : 2018R
Hikma Pharmaceuticals Plc
23 October 2013
Notification of major interests in shares
LONDON, 23 October 2013 - Hikma Pharmaceuticals PLC ("Hikma")
(LSE: HIK) (DIFX: HIK), the fast growing multinational
pharmaceuticals group, announces as follows:
1 Identity of the issuer or the underlying Hikma Pharmaceuticals PLC
issuer of existing shares to which the
voting rights are attached
----------------------------------------- --------------------------
2 Reason for the notification
--------------------------------------------------------- ----
An acquisition or disposal of voting rights Yes
--------------------------------------------------------- ----
An acquisition or disposal of financial instruments No
which may result in the acquisition of shares already
issues to which voting rights are attached
--------------------------------------------------------- ----
An event changing the breakdown of voting rights No
--------------------------------------------------------- ----
Other (please specify): Compliance with the Transparency No
Directive
--------------------------------------------------------- ----
3 Full name of the person subject to the The Capital Group Companies,
notification obligation Inc
----- ---------------------------------------------------------------- --------------------------------------
4 Full name of shareholders Capital Research and Management
Company SMALLCAP World
Fund, Inc & Capital Research
and Management Company
New World Fund, Inc
----- ---------------------------------------------------------------- --------------------------------------
5 Date of the Transaction (and date on 21 October 2013
which the threshold crossed is reached
differently)
----- ---------------------------------------------------------------- --------------------------------------
6 Date on which the issuer notified 23 October 2013
----- ---------------------------------------------------------------- --------------------------------------
7 Threshold that is crossed 10%
----- ---------------------------------------------------------------- --------------------------------------
8 Notified details See A, B & C below
----- ---------------------------------------------------------------- --------------------------------------
A. Voting rights attached to shares
---------------------------------------------------------------------------------------------------------------
Class type Situation previous Resulting situation after the triggering
of shares to the triggering transaction
(if possible transaction
using the
ISIN code)
---------------- ------------------------ -------------------------------------------------------------------
Number Number Number of shares Number of voting % of voting
of shares of voting rights rights
rights
----- --------- ----------- ----------- -------------------- ---------------------- ---------------------
Direct Indirect Direct Indirect Direct Indirect
----- --------- ----------- ----------- ------- ----------- --------- ----------- ------- ------------
Ordinary
Shares (0.10
GBP)
GB00B0LCW083 19,807,981 19,807,981 0 19,807,981 0 19,807,981 0% 10.016%
---------------- ----------- ----------- ------- ----------- --------- ----------- ------- ------------
B. Qualifying Financial instruments
----------------------------------------------------------------------------------------------------
Resulting situation after the triggering transaction
----------------------------------------------------------------------------------------------------
Type of financial Expiration Exercise/Conversion Number of voting % of voting rights
instrument Date Period/Date rights that may
be acquired if
the instrument
if exercised/converted
------------------ ----------- -------------------- ------------------------ -------------------
- - - - -
------------------ ----------- -------------------- ------------------------ -------------------
C: Financial Instruments with similar economic effect to Qualifying
Financial Instruments
------------------------------------------------------------------------------------------------------
Resulting situation after the triggering transaction
------------------------------------------------------------------------------------------------------
Type of Exercise Expiration Exercise/Conversion Number of voting % of voting rights
financial Price Date Period/Date rights instrument
instrument refers to
------------ --------- ----------- -------------------- ------------------- ---------------------
Nominal Delta
------------ --------- ----------- -------------------- ------------------- ----------- --------
- - - - - - -
------------ --------- ----------- -------------------- ------------------- ----------- --------
Total A+B+C
---------------------------------------------
Number of Voting rights % of voting rights
------------------------ -------------------
19,807,981 10.016%
------------------------ -------------------
9 Chain of controlled undertakings through which the voting rights
and/or the financial instruments are effectively held, if applicable
----------------------------------------------------------------------
Proxy Voting
----------------------------------------------------------------------
10 Name of the proxy holder The Capital Group Companies, Inc
--- ------------------------------ ---------------------------------
11 Number of voting rights proxy N/A
holder will cease to hold
--- ------------------------------ ---------------------------------
12 Date on which proxy holder N/A
will cease to hold voting
rights
--- ------------------------------ ---------------------------------
13 Additional Information
--- -------------------------- --------------------------------
14 Contact name: Peter Speirs, Company Secretary
--- -------------------------- --------------------------------
15 Contact telephone number: 020 7399 2772
--- -------------------------- --------------------------------
- ENDS -
About Hikma
Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group
focused on developing, manufacturing and marketing a broad range of
both branded and non-branded generic and in-licensed products.
Hikma's operations are conducted through three businesses:
"Branded", "Injectables" and "Generics" based primarily in the
Middle East and North Africa ("MENA") region, where it is a market
leader, the United States and Europe. In 2012, Hikma achieved
revenues of $1,108.7 million and profit attributable to
shareholders of $100.3 million.
This information is provided by RNS
The company news service from the London Stock Exchange
END
HOLUOORROBARUAA
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jul 2023 to Jul 2024
